At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
LY3314814 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Absolute Bioavailability Study of LY3314814 in Healthy Subjects Using an Intravenous Tracer Method
In Brief
A Phase 1 clinical trial evaluating LY3314814 and [13C415N3] LY3314814 for Healthy. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The purpose of this study is to measure how much LY3314814 gets into the bloodstream when it is given as a single dose by mouth and as an intravenous (IV) infusion over two hours. The study will last at least two weeks for each participant, not including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
CollaboratorsEli Lilly and Company
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartJan 2018
Primary CompletionFeb 2018
TodayJul 2026
First PostedJul 19, 2017
Enrollment StartJan 15, 2018
Primary CompletionFeb 16, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 9.0 years ago
Interventions
LY3314814drug
Administered orally
[13C415N3] LY3314814drug
Administered as an IV infusion